TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02049593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor BMN-673
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor BMN-673
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02055118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: idursulfase-IT
Description: 10mg

Intervention type: OTHER
Group type: OTHER
Intervention: No IT treatment
Description: Standard of Care
Study: NCT00646269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention protocol
Description: The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard intervention protocol + Cognitive training therapy
Description: Cognitive training therapy is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving...) related to activities of daily living is realized at each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard intervention protocol + Reminiscence therapy
Description: Reminiscence therapy is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard intervention protocol + Made-to-measure program
Description: The made to measure program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies (Cognitive training therapy or Reminiscence therapy) the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs.
Study: NCT00726011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: 30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
Study: NCT03944252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
Study: NCT02561338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: 75mgQD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: 100mgQD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: 50mgBID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: 75mgBID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD/BID
Study: NCT01785485

Intervention type: OTHER
Intervention: Integrative medicine primary care model
Description: An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
Study: NCT01147913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Information-Processing Bias Retraining
Description: The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control Training
Description: Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression.
Study: NCT04541459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: new device against ambient electromagnetic radiation
Description: New device provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham device against ambient electromagnetic radiation
Description: Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
Study: NCT03766152

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive bone conduction hearing aid (ADHEAR - Med El)
Description: Patients are asked to wear an adhesive bone conduction hearing device which is attached to the mastoid with an adhesive adapter
Study: NCT01033448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPEGUS
Description: COPEGUS 800 mg or 1000-1200 mg po for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: PEGASYS 180 micrograms sc once weekly for 24 weeks
Study: NCT01744080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Wait Time
Description: Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Surgery
Description: Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
Study: NCT01170572

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01273753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intradialytic exercise
Description: Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
Study: NCT04208607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Role of bronchoscopy in diagnosis of bronchiectasis
Study: NCT01763840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast enhanced Ultrasound
Description: Ultrasound, then contrast enhanced ultrasound.
Study: NCT00899431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenously daily on days -5, -4, -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenously daily on days -5, -4, -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: 1.0 mg/kg intravenously over 4 hours (day -2 and -1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: 1.0 mg/kg intravenously over 4 hours (day -2 and -1).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplantation
Description: On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplantation
Description: On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
Study: NCT04509661

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LABA/LAMA or Placebo inhalation
Description: Inhaled LABA/LAMA for one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/LAMA or Placebo inhalation
Description: Inhaled LABA/LAMA for one year.
Study: NCT02860429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini injection
Description: cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Chemotherapy is the oxaliplatin combination with fluorouracil regimen.

Intervention type: DRUG
Group type: OTHER
Intervention: chemotherapy
Description: Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
Study: NCT00006289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tabs b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tabs b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: 4 tabs b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: 4 tabs b.i.d.
Study: NCT02098668

Intervention type: OTHER
Intervention: Fertility treatment
Description: Fertility treatment
Study: NCT02465099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Dissection (UD)
Description: Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery Dissection (ED)
Description: Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF
Study: NCT01966848

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wich prosthesis is used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wich prosthesis is used
Study: NCT02605460

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.

Intervention type: DRUG
Group type: OTHER
Intervention: CXCR4 Antagonist
Description: 24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic Stem Cell Transplantation
Description: Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
Study: NCT00703248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatments
Description: 1. opening the thoracic inlet~2. pectoral traction for 1 minute bilaterally~3. rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine \]~4. thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~5. abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally.
Study: NCT02706262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolically abnormal obese - Mediterranean diet
Description: The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolically abnormal obese - Low carbohydrate ketogenic diet
Description: The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolically abnormal obese - Plant-based, very-low-fat diet
Description: The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
Study: NCT00773604

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic implantable deep brain stimulation (DBS) system
Description: surgical placement of deep brain stimulation system for treatment of dystonia
Study: NCT03727724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection
Study: NCT04282330

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D CEST imaging
Description: Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
Study: NCT03159793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Modelling Technique
Description: Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Filmed Modelling technique
Description: Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
Study: NCT03520504

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton craniospinal irradiation (CSI)
Description: Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
Study: NCT04112381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Model 4000 Type 1.0/1.1
Description: Exablate thalamotomy of non tremor dominant side of the brain
Study: NCT03339752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: 25 mg hard capsule

Intervention type: DRUG
Group type: OTHER
Intervention: ACT-541468
Description: 25 mg hard capsule
Study: NCT03462693

Intervention type: OTHER
Intervention: Dry needling
Description: The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
Study: NCT01148979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (Vyvanse)
Description: Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
Study: NCT00056069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
Study: NCT01646125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
Study: NCT01516541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background care
Description: Guidelines-based medical care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Background care
Description: Guidelines-based medical care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching dalcetrapib placebo orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: 600 mg orally daily
Study: NCT02978781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matching placebo capsules
Study: NCT01757925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight managment program
Description: a comprehensive peditric weight management program consisting of 16 weekly group sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight managment program
Description: a comprehensive peditric weight management program consisting of 16 weekly group sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Gaming
Description: partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
Study: NCT04678219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
Study: NCT01549418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (ASA)
Description: Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04040933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Adhesive Bandage #1
Description: On the randomized wound site, a marketed adhesive bandage will be applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Bandage #2
Description: On the randomized wound site, a marketed adhesive bandage will be applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Marketed Bandage #1
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Bandage #2
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Adhesive Bandage #3
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Adhesive Bandage #4
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Adhesive Bandage #5
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.